Influenza
Conditions
Brief summary
This study evaluates the immunogenicity and safety of 'IL-YANG Quadrivalent Influenza Vaccine Inj.' in healthy male and female adults at the age of 19 or older.
Detailed description
In this study, only eligible subjects for the study based on the inclusion/exclusion criteria will be randomized to the following stratification groups by age to receive one dose of the test vaccine, comparator 1, or comparator 2. * Group A: healthy adults at the age of ≥ 19 and \< 65. * Group B: healthy adults at the age of ≥ 65. During the study participation, the investigator will assess immunogenicity and safety in subjects. The investigator will perform immunogenicity tests at Visits 1 and 3 (end of study visit) for immunogenicity evaluation (prior to the investigational product vaccination) and instruct subjects to record AEs occurring after the investigational product vaccination for safety assessment. A blood sample will be collected from a subject who is assigned a subject number. Following an intramuscular injection of 0.5mL investigational product in the deltoid muscle of the shoulder, the subject will have a study visit on Week 4 for blood sampling for antibody titer testing. In addition, a telephone visit will be performed to assess serious AEs (SAEs) up to Day 180 after vaccination.
Interventions
BIOLOGICALIL-YANG Quadrivalent Influenza Vaccine
A single 0.5mL dose administrated as an intramuscular injection.
BIOLOGICALIL-YANG Flu Vaccine Prefilled Syringe
A single 0.5mL dose administrated as an intramuscular injection.
BIOLOGICALIL-YANG Trivalent Influenza Vaccine
A single 0.5mL dose administrated as an intramuscular injection.
Sponsors
Il-Yang Pharm. Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Healthy men and women at the age of 19 or older. * Women of childbearing potential must have a negative pregnancy test (urine HCG) at the screening visit. * Subjects who were given, and fully understood, the information about the study, and have provided voluntary written informed consent to participate in the study and to comply with all applicable study requirements.
Exclusion criteria
* Subjects with known allergy to eggs, chicken, or any components of the study vaccine. * Subjects who had received an influenza vaccine within the last 6 months prior to study entry. * Subjects who have immune function disorders including immunodeficiency diseases or relevant family history. * Subjects who donated blood within 1 week prior to vaccination or plan to donate blood during the period from Day 1 to Month 7 of vaccination. * Subjects with a history of Guillain-Barre syndrome. * Subjects with Down's syndrome or cytogenetic disorders. * Subjects who are considered by the investigator to have difficulties in study participation due to severe chronic diseases (e.g., cardiovascular diseases except controlled hypertension and respiratory diseases with respiratory failure, metabolic diseases, renal function disorders, hemoglobinopathy, etc.). * Subjects with hemophilia or coagulation disorder, who are at increased risk of serious bleeding during intramuscular injection. * Subjects who had an acute fever with body temperature \> 38.0 ºC within 72 hours prior to administration of the study vaccine. * Subjects who had received another vaccine within 28 days before administration of the study vaccine or are planning to receive another vaccine during the study. * Subjects who had received immunosuppressants or immune modifying drugs within 3 months prior to the investigational product vaccination. 1. Azathioprine, cyclosporin, interferon, G-CSF, tacrolimus, everolimus, sirolimus, etc. 2. High dose corticosteroids (a subject taking high doses, which is defined as 2mg/kg/day or higher of prednisolone administered for longer than 14 consecutive days, is not eligible for this study. The use of inhaled, nasal and topical corticosteroids is allowed, regardless of doses). * Subjects who had previously received immunoglobulin or blood-derived products within the last 3 months prior to administration of the study vaccine, or are scheduled to receive a treatment with blood-derived products during the study. * Subjects who had participated in another clinical trial within the 30 days before administration of the study vaccine. * Female subjects of childbearing potential who do not agree to use an acceptable method of birth control\* for this study during the study period. * Medically acceptable methods of birth control: condom, injectable or implantable contraceptives, intrauterine device, or oral contraceptives, etc. * Subjects with other clinically significant medical or psychiatric illness who in the investigator's opinion, are not be suitable for the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of Healthy Adults Aged ≥19 Years With Seroconversion | Day 28 | Seroconversion is defined as follows. (Case 1) A pre-vaccination (Day 0) HI antibody titer \< 1:10 and a post-vaccination (Day 28) HI antibody titer ≥ 1: 40. or (Case 2) a pre-vaccination (Day 0) HI antibody titer ≥ 1:10 and a minimum four-fold rise in post-vaccination (Day 28) HI antibody titer. |
| Rate of Healthy Adults Aged ≥19 Years With Seroprotection | Day 28 | Seroprotection: A post-vaccination (Day 28) HI antibody titer ≥ 1:40. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Geometric Mean Titer as Measured by HI Antibody Titer on Day 28 After Vaccination of the Investigational Product (GMTcomparator/GMTtest Vaccine). | Day 28 | — |
| Difference of Seroconversion Rate(SCR) of HI Antibody Titer After 28days Vaccination(SCRcomparator-SCRtest Vaccine) | Day 28 | The IL-YANG Quadrivalent Influenza Vaccine contain two types of B strain, while two kinds of Trivalent Influenza Vaccine contain each type of B strain. Primary outcome was about seroconversion and seroprotection rate of HI antibody, so each results of 3 kinds of vaccine was described. Considering the cross-reaction between two types of B strain, the analysis was designed in a way that the SCR/SPR of the B strains can be compared, respectively. However, secondary outcome, unlike the primary outcome, is expressed as a ratio(difference of seroconversion rate). So, the above factors were not to be consider. All methods of analysis are comply with the request of MFDS, and the result data that may make you confuse will be delete. |
| Percentage of Subjects With SCR on Day 28 After Vaccination of the Investigational Product by Age Group | Day 28 | The percentage of subjects with HI antibody SCR on Day 28 after vaccination of the investigational product was calculated and its 95% two-sided CI was presented for each strain by treatment group and by age group. The immunogenicity of the test vaccine was to be demonstrated if the lower limit of the 95% two-sided CI by age group was higher than the above mentioned criteria (40% for \< 65 years of age, 30% for ≥ 65 years of age) in each treatment group. |
| Geometric Mean Ratio as Measured by HI Antibody Titer Before (Day 0) and on Day 28 After Vaccination of the Investigational Product. | Day 28 | — |
| Geometric Mean Titer as Measured by HI Antibody Titer Before (Day 0) and on Day 28 After Vaccination of the Investigational Product. | Day 28 | — |
| Rate of Healthy Adults Aged ≥19 ~ <65 Years and ≥65 Years With Seroprotection, Respectively. | Day 28 | Seroprotection is defined as follows. subjects who have a post-vaccination (Day 28) HI antibody titer ≥ 1: 40 |
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| IL-YANG Quadrivalent Influenza Vaccine The QIV is included both B strain (Yamagata, Victoria).
IL-YANG Quadrivalent Influenza Vaccine: A single 0.5mL dose administrated as an intramuscular injection. | 1,197 |
| IL-YANG Flu Vaccine Prefilled Syringe This TIV is included the B/Yamagata strain, and it was approved for commercial sale by MFDS.
IL-YANG Flu Vaccine Prefilled Syringe: A single 0.5mL dose administrated as an intramuscular injection. | 298 |
| IL-YANG Trivalent Influenza Vaccine This TIV is included the B/Victoria strain.
IL-YANG Trivalent Influenza Vaccine: A single 0.5mL dose administrated as an intramuscular injection. | 299 |
| Total | 1,794 |
Baseline characteristics
| Characteristic | Total | IL-YANG Quadrivalent Influenza Vaccine | IL-YANG Flu Vaccine Prefilled Syringe | IL-YANG Trivalent Influenza Vaccine |
|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 272 Participants | 182 Participants | 44 Participants | 46 Participants |
| Age, Categorical Between 18 and 65 years | 1522 Participants | 1015 Participants | 254 Participants | 253 Participants |
| Age, Continuous | 44.8 years STANDARD_DEVIATION 14.6 | 44.7 years STANDARD_DEVIATION 14.5 | 44.5 years STANDARD_DEVIATION 14.7 | 45.7 years STANDARD_DEVIATION 14.6 |
| Sex: Female, Male Female | 1224 Participants | 812 Participants | 208 Participants | 204 Participants |
| Sex: Female, Male Male | 570 Participants | 385 Participants | 90 Participants | 95 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — |
| other Total, other adverse events | 0 / 1,194 | 0 / 298 | 0 / 299 |
| serious Total, serious adverse events | 0 / 1,194 | 2 / 298 | 1 / 299 |
Outcome results
Primary
Rate of Healthy Adults Aged ≥19 Years With Seroconversion
Seroconversion is defined as follows. (Case 1) A pre-vaccination (Day 0) HI antibody titer \< 1:10 and a post-vaccination (Day 28) HI antibody titer ≥ 1: 40. or (Case 2) a pre-vaccination (Day 0) HI antibody titer ≥ 1:10 and a minimum four-fold rise in post-vaccination (Day 28) HI antibody titer.
Time frame: Day 28
Population: The immunogenicity data obtained from the study subjects were analyzed primarily in the Per Protocol Set that was consists of subjects who had at least one dose of the investigational product and from whom post-treatment primary efficacy endpoint data, and have completed the study up to Visit 3 without a major protocol violation.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| IL-YANG Quadrivalent Influenza Vaccine | Rate of Healthy Adults Aged ≥19 Years With Seroconversion | A/H1N1 | 47.7 percentage of subjects |
| IL-YANG Quadrivalent Influenza Vaccine | Rate of Healthy Adults Aged ≥19 Years With Seroconversion | A/H3N2 | 78.7 percentage of subjects |
| IL-YANG Quadrivalent Influenza Vaccine | Rate of Healthy Adults Aged ≥19 Years With Seroconversion | B/Yamagata | 51.8 percentage of subjects |
| IL-YANG Quadrivalent Influenza Vaccine | Rate of Healthy Adults Aged ≥19 Years With Seroconversion | B/Victoria | 47.7 percentage of subjects |
| IL-YANG Quadrivalent Influenza Vaccine | Rate of Healthy Adults Aged ≥19 Years With Seroconversion | B/Victoria | 24.2 percentage of subjects |
| IL-YANG Quadrivalent Influenza Vaccine | Rate of Healthy Adults Aged ≥19 Years With Seroconversion | A/H1N1 | 49.5 percentage of subjects |
| IL-YANG Quadrivalent Influenza Vaccine | Rate of Healthy Adults Aged ≥19 Years With Seroconversion | B/Yamagata | 54.9 percentage of subjects |
| IL-YANG Quadrivalent Influenza Vaccine | Rate of Healthy Adults Aged ≥19 Years With Seroconversion | A/H3N2 | 81.6 percentage of subjects |
| IL-YANG Trivalent Influenza Vaccine | Rate of Healthy Adults Aged ≥19 Years With Seroconversion | B/Victoria | 54.8 percentage of subjects |
| IL-YANG Trivalent Influenza Vaccine | Rate of Healthy Adults Aged ≥19 Years With Seroconversion | A/H3N2 | 77.9 percentage of subjects |
| IL-YANG Trivalent Influenza Vaccine | Rate of Healthy Adults Aged ≥19 Years With Seroconversion | B/Yamagata | 23.1 percentage of subjects |
| IL-YANG Trivalent Influenza Vaccine | Rate of Healthy Adults Aged ≥19 Years With Seroconversion | A/H1N1 | 49.0 percentage of subjects |
Primary
Rate of Healthy Adults Aged ≥19 Years With Seroprotection
Seroprotection: A post-vaccination (Day 28) HI antibody titer ≥ 1:40.
Time frame: Day 28
Population: The immunogenicity data obtained from the study subjects were analyzed primarily in the Per Protocol Set that was consists of subjects who had at least one dose of the investigational product and from whom post-treatment primary efficacy endpoint data, and have completed the study up to Visit 3 without a major protocol violation.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| IL-YANG Quadrivalent Influenza Vaccine | Rate of Healthy Adults Aged ≥19 Years With Seroprotection | A/H1N1 | 88.2 percentage of subjects |
| IL-YANG Quadrivalent Influenza Vaccine | Rate of Healthy Adults Aged ≥19 Years With Seroprotection | A/H3N2 | 90.0 percentage of subjects |
| IL-YANG Quadrivalent Influenza Vaccine | Rate of Healthy Adults Aged ≥19 Years With Seroprotection | B/Yamagata | 86.3 percentage of subjects |
| IL-YANG Quadrivalent Influenza Vaccine | Rate of Healthy Adults Aged ≥19 Years With Seroprotection | B/Victoria | 84.9 percentage of subjects |
| IL-YANG Quadrivalent Influenza Vaccine | Rate of Healthy Adults Aged ≥19 Years With Seroprotection | B/Victoria | 69.3 percentage of subjects |
| IL-YANG Quadrivalent Influenza Vaccine | Rate of Healthy Adults Aged ≥19 Years With Seroprotection | A/H1N1 | 89.4 percentage of subjects |
| IL-YANG Quadrivalent Influenza Vaccine | Rate of Healthy Adults Aged ≥19 Years With Seroprotection | B/Yamagata | 88.4 percentage of subjects |
| IL-YANG Quadrivalent Influenza Vaccine | Rate of Healthy Adults Aged ≥19 Years With Seroprotection | A/H3N2 | 92.5 percentage of subjects |
| IL-YANG Trivalent Influenza Vaccine | Rate of Healthy Adults Aged ≥19 Years With Seroprotection | B/Victoria | 85.7 percentage of subjects |
| IL-YANG Trivalent Influenza Vaccine | Rate of Healthy Adults Aged ≥19 Years With Seroprotection | A/H3N2 | 89.5 percentage of subjects |
| IL-YANG Trivalent Influenza Vaccine | Rate of Healthy Adults Aged ≥19 Years With Seroprotection | B/Yamagata | 64.6 percentage of subjects |
| IL-YANG Trivalent Influenza Vaccine | Rate of Healthy Adults Aged ≥19 Years With Seroprotection | A/H1N1 | 87.1 percentage of subjects |
Comparison: To evaluate if the seroconversion (SCR) and seroprotection (SPR) rates on Day 28 after vaccination of IL-YANG Quadrivalent Influenza Vaccine Inj. meet the following criteria in all age groups of healthy male and female adults at the age of 19 or older.p-value: 0.09135ANCOVA
Secondary
Difference of Seroconversion Rate(SCR) of HI Antibody Titer After 28days Vaccination(SCRcomparator-SCRtest Vaccine)
The IL-YANG Quadrivalent Influenza Vaccine contain two types of B strain, while two kinds of Trivalent Influenza Vaccine contain each type of B strain. Primary outcome was about seroconversion and seroprotection rate of HI antibody, so each results of 3 kinds of vaccine was described. Considering the cross-reaction between two types of B strain, the analysis was designed in a way that the SCR/SPR of the B strains can be compared, respectively. However, secondary outcome, unlike the primary outcome, is expressed as a ratio(difference of seroconversion rate). So, the above factors were not to be consider. All methods of analysis are comply with the request of MFDS, and the result data that may make you confuse will be delete.
Time frame: Day 28
Population: Please see Outcome Measure Description and Arm/Group Descriptionabove.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| IL-YANG Quadrivalent Influenza Vaccine | Difference of Seroconversion Rate(SCR) of HI Antibody Titer After 28days Vaccination(SCRcomparator-SCRtest Vaccine) | Strain H1N1 | 49.2 percentage of participants |
| IL-YANG Quadrivalent Influenza Vaccine | Difference of Seroconversion Rate(SCR) of HI Antibody Titer After 28days Vaccination(SCRcomparator-SCRtest Vaccine) | Strain H3N2 | 79.7 percentage of participants |
| IL-YANG Quadrivalent Influenza Vaccine | Difference of Seroconversion Rate(SCR) of HI Antibody Titer After 28days Vaccination(SCRcomparator-SCRtest Vaccine) | Strain B Yamagata | 54.9 percentage of participants |
| IL-YANG Quadrivalent Influenza Vaccine | Difference of Seroconversion Rate(SCR) of HI Antibody Titer After 28days Vaccination(SCRcomparator-SCRtest Vaccine) | Strain B Victoria | 54.8 percentage of participants |
| IL-YANG Quadrivalent Influenza Vaccine | Difference of Seroconversion Rate(SCR) of HI Antibody Titer After 28days Vaccination(SCRcomparator-SCRtest Vaccine) | Strain B Victoria | 47.7 percentage of participants |
| IL-YANG Quadrivalent Influenza Vaccine | Difference of Seroconversion Rate(SCR) of HI Antibody Titer After 28days Vaccination(SCRcomparator-SCRtest Vaccine) | Strain H1N1 | 47.7 percentage of participants |
| IL-YANG Quadrivalent Influenza Vaccine | Difference of Seroconversion Rate(SCR) of HI Antibody Titer After 28days Vaccination(SCRcomparator-SCRtest Vaccine) | Strain B Yamagata | 51.8 percentage of participants |
| IL-YANG Quadrivalent Influenza Vaccine | Difference of Seroconversion Rate(SCR) of HI Antibody Titer After 28days Vaccination(SCRcomparator-SCRtest Vaccine) | Strain H3N2 | 78.7 percentage of participants |
Secondary
Geometric Mean Ratio as Measured by HI Antibody Titer Before (Day 0) and on Day 28 After Vaccination of the Investigational Product.
Time frame: Day 28
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| IL-YANG Quadrivalent Influenza Vaccine | Geometric Mean Ratio as Measured by HI Antibody Titer Before (Day 0) and on Day 28 After Vaccination of the Investigational Product. | Strain H1N1 | 3.9 Ratio of GMT titer |
| IL-YANG Quadrivalent Influenza Vaccine | Geometric Mean Ratio as Measured by HI Antibody Titer Before (Day 0) and on Day 28 After Vaccination of the Investigational Product. | Strain H3N2 | 9.5 Ratio of GMT titer |
| IL-YANG Quadrivalent Influenza Vaccine | Geometric Mean Ratio as Measured by HI Antibody Titer Before (Day 0) and on Day 28 After Vaccination of the Investigational Product. | Strain B Yamagata | 3.3 Ratio of GMT titer |
| IL-YANG Quadrivalent Influenza Vaccine | Geometric Mean Ratio as Measured by HI Antibody Titer Before (Day 0) and on Day 28 After Vaccination of the Investigational Product. | Strain B Victoria | 2.9 Ratio of GMT titer |
| IL-YANG Quadrivalent Influenza Vaccine | Geometric Mean Ratio as Measured by HI Antibody Titer Before (Day 0) and on Day 28 After Vaccination of the Investigational Product. | Strain B Victoria | 2.1 Ratio of GMT titer |
| IL-YANG Quadrivalent Influenza Vaccine | Geometric Mean Ratio as Measured by HI Antibody Titer Before (Day 0) and on Day 28 After Vaccination of the Investigational Product. | Strain H1N1 | 4.1 Ratio of GMT titer |
| IL-YANG Quadrivalent Influenza Vaccine | Geometric Mean Ratio as Measured by HI Antibody Titer Before (Day 0) and on Day 28 After Vaccination of the Investigational Product. | Strain B Yamagata | 3.5 Ratio of GMT titer |
| IL-YANG Quadrivalent Influenza Vaccine | Geometric Mean Ratio as Measured by HI Antibody Titer Before (Day 0) and on Day 28 After Vaccination of the Investigational Product. | Strain H3N2 | 10.9 Ratio of GMT titer |
| IL-YANG Trivalent Influenza Vaccine | Geometric Mean Ratio as Measured by HI Antibody Titer Before (Day 0) and on Day 28 After Vaccination of the Investigational Product. | Strain B Victoria | 3.0 Ratio of GMT titer |
| IL-YANG Trivalent Influenza Vaccine | Geometric Mean Ratio as Measured by HI Antibody Titer Before (Day 0) and on Day 28 After Vaccination of the Investigational Product. | Strain H3N2 | 9.8 Ratio of GMT titer |
| IL-YANG Trivalent Influenza Vaccine | Geometric Mean Ratio as Measured by HI Antibody Titer Before (Day 0) and on Day 28 After Vaccination of the Investigational Product. | Strain B Yamagata | 2.0 Ratio of GMT titer |
| IL-YANG Trivalent Influenza Vaccine | Geometric Mean Ratio as Measured by HI Antibody Titer Before (Day 0) and on Day 28 After Vaccination of the Investigational Product. | Strain H1N1 | 3.7 Ratio of GMT titer |
Secondary
Geometric Mean Titer as Measured by HI Antibody Titer Before (Day 0) and on Day 28 After Vaccination of the Investigational Product.
Time frame: Day 28
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| IL-YANG Quadrivalent Influenza Vaccine | Geometric Mean Titer as Measured by HI Antibody Titer Before (Day 0) and on Day 28 After Vaccination of the Investigational Product. | Strain B Yamagata | 74.3 Titer |
| IL-YANG Quadrivalent Influenza Vaccine | Geometric Mean Titer as Measured by HI Antibody Titer Before (Day 0) and on Day 28 After Vaccination of the Investigational Product. | Strain B Victoria | 60.1 Titer |
| IL-YANG Quadrivalent Influenza Vaccine | Geometric Mean Titer as Measured by HI Antibody Titer Before (Day 0) and on Day 28 After Vaccination of the Investigational Product. | Strain H1N1 | 82.2 Titer |
| IL-YANG Quadrivalent Influenza Vaccine | Geometric Mean Titer as Measured by HI Antibody Titer Before (Day 0) and on Day 28 After Vaccination of the Investigational Product. | Strain H3N2 | 127.6 Titer |
| IL-YANG Quadrivalent Influenza Vaccine | Geometric Mean Titer as Measured by HI Antibody Titer Before (Day 0) and on Day 28 After Vaccination of the Investigational Product. | Strain B Yamagata | 75.9 Titer |
| IL-YANG Quadrivalent Influenza Vaccine | Geometric Mean Titer as Measured by HI Antibody Titer Before (Day 0) and on Day 28 After Vaccination of the Investigational Product. | Strain H3N2 | 135.6 Titer |
| IL-YANG Quadrivalent Influenza Vaccine | Geometric Mean Titer as Measured by HI Antibody Titer Before (Day 0) and on Day 28 After Vaccination of the Investigational Product. | Strain B Victoria | 41.2 Titer |
| IL-YANG Quadrivalent Influenza Vaccine | Geometric Mean Titer as Measured by HI Antibody Titer Before (Day 0) and on Day 28 After Vaccination of the Investigational Product. | Strain H1N1 | 89.8 Titer |
| IL-YANG Trivalent Influenza Vaccine | Geometric Mean Titer as Measured by HI Antibody Titer Before (Day 0) and on Day 28 After Vaccination of the Investigational Product. | Strain B Victoria | 62.0 Titer |
| IL-YANG Trivalent Influenza Vaccine | Geometric Mean Titer as Measured by HI Antibody Titer Before (Day 0) and on Day 28 After Vaccination of the Investigational Product. | Strain H1N1 | 80.6 Titer |
| IL-YANG Trivalent Influenza Vaccine | Geometric Mean Titer as Measured by HI Antibody Titer Before (Day 0) and on Day 28 After Vaccination of the Investigational Product. | Strain H3N2 | 125.8 Titer |
| IL-YANG Trivalent Influenza Vaccine | Geometric Mean Titer as Measured by HI Antibody Titer Before (Day 0) and on Day 28 After Vaccination of the Investigational Product. | Strain B Yamagata | 44.0 Titer |
Secondary
Geometric Mean Titer as Measured by HI Antibody Titer on Day 28 After Vaccination of the Investigational Product (GMTcomparator/GMTtest Vaccine).
Time frame: Day 28
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| IL-YANG Quadrivalent Influenza Vaccine | Geometric Mean Titer as Measured by HI Antibody Titer on Day 28 After Vaccination of the Investigational Product (GMTcomparator/GMTtest Vaccine). | Strain H1N1 | 82.2 Titer |
| IL-YANG Quadrivalent Influenza Vaccine | Geometric Mean Titer as Measured by HI Antibody Titer on Day 28 After Vaccination of the Investigational Product (GMTcomparator/GMTtest Vaccine). | Strain H3N2 | 127.6 Titer |
| IL-YANG Quadrivalent Influenza Vaccine | Geometric Mean Titer as Measured by HI Antibody Titer on Day 28 After Vaccination of the Investigational Product (GMTcomparator/GMTtest Vaccine). | Strain B Yamagata | 74.3 Titer |
| IL-YANG Quadrivalent Influenza Vaccine | Geometric Mean Titer as Measured by HI Antibody Titer on Day 28 After Vaccination of the Investigational Product (GMTcomparator/GMTtest Vaccine). | Strain B Victoria | 60.1 Titer |
| IL-YANG Quadrivalent Influenza Vaccine | Geometric Mean Titer as Measured by HI Antibody Titer on Day 28 After Vaccination of the Investigational Product (GMTcomparator/GMTtest Vaccine). | Strain B Victoria | 62.0 Titer |
| IL-YANG Quadrivalent Influenza Vaccine | Geometric Mean Titer as Measured by HI Antibody Titer on Day 28 After Vaccination of the Investigational Product (GMTcomparator/GMTtest Vaccine). | Strain H1N1 | 85.1 Titer |
| IL-YANG Quadrivalent Influenza Vaccine | Geometric Mean Titer as Measured by HI Antibody Titer on Day 28 After Vaccination of the Investigational Product (GMTcomparator/GMTtest Vaccine). | Strain B Yamagata | 75.9 Titer |
| IL-YANG Quadrivalent Influenza Vaccine | Geometric Mean Titer as Measured by HI Antibody Titer on Day 28 After Vaccination of the Investigational Product (GMTcomparator/GMTtest Vaccine). | Strain H3N2 | 130.6 Titer |
Secondary
Percentage of Subjects With SCR on Day 28 After Vaccination of the Investigational Product by Age Group
The percentage of subjects with HI antibody SCR on Day 28 after vaccination of the investigational product was calculated and its 95% two-sided CI was presented for each strain by treatment group and by age group. The immunogenicity of the test vaccine was to be demonstrated if the lower limit of the 95% two-sided CI by age group was higher than the above mentioned criteria (40% for \< 65 years of age, 30% for ≥ 65 years of age) in each treatment group.
Time frame: Day 28
Population: Rate of healthy adults aged ≥19 \~ \<65 years
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| IL-YANG Quadrivalent Influenza Vaccine | Percentage of Subjects With SCR on Day 28 After Vaccination of the Investigational Product by Age Group | Strain H1N1 | 48.7 percentage of participants |
| IL-YANG Quadrivalent Influenza Vaccine | Percentage of Subjects With SCR on Day 28 After Vaccination of the Investigational Product by Age Group | Strain H3N2 | 80.3 percentage of participants |
| IL-YANG Quadrivalent Influenza Vaccine | Percentage of Subjects With SCR on Day 28 After Vaccination of the Investigational Product by Age Group | Strain B Yamagata | 52.3 percentage of participants |
| IL-YANG Quadrivalent Influenza Vaccine | Percentage of Subjects With SCR on Day 28 After Vaccination of the Investigational Product by Age Group | Strain B Victoria | 48.3 percentage of participants |
| IL-YANG Quadrivalent Influenza Vaccine | Percentage of Subjects With SCR on Day 28 After Vaccination of the Investigational Product by Age Group | Strain B Victoria | 27.5 percentage of participants |
| IL-YANG Quadrivalent Influenza Vaccine | Percentage of Subjects With SCR on Day 28 After Vaccination of the Investigational Product by Age Group | Strain H1N1 | 51.8 percentage of participants |
| IL-YANG Quadrivalent Influenza Vaccine | Percentage of Subjects With SCR on Day 28 After Vaccination of the Investigational Product by Age Group | Strain B Yamagata | 54.6 percentage of participants |
| IL-YANG Quadrivalent Influenza Vaccine | Percentage of Subjects With SCR on Day 28 After Vaccination of the Investigational Product by Age Group | Strain H3N2 | 83.3 percentage of participants |
| IL-YANG Trivalent Influenza Vaccine | Percentage of Subjects With SCR on Day 28 After Vaccination of the Investigational Product by Age Group | Strain B Victoria | 56.6 percentage of participants |
| IL-YANG Trivalent Influenza Vaccine | Percentage of Subjects With SCR on Day 28 After Vaccination of the Investigational Product by Age Group | Strain H3N2 | 78.7 percentage of participants |
| IL-YANG Trivalent Influenza Vaccine | Percentage of Subjects With SCR on Day 28 After Vaccination of the Investigational Product by Age Group | Strain B Yamagata | 24.5 percentage of participants |
| IL-YANG Trivalent Influenza Vaccine | Percentage of Subjects With SCR on Day 28 After Vaccination of the Investigational Product by Age Group | Strain H1N1 | 51.8 percentage of participants |
Secondary
Rate of Healthy Adults Aged ≥19 ~ <65 Years and ≥65 Years With Seroprotection, Respectively.
Seroprotection is defined as follows. subjects who have a post-vaccination (Day 28) HI antibody titer ≥ 1: 40
Time frame: Day 28
Population: Rate of healthy adults aged ≥65 years
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| IL-YANG Quadrivalent Influenza Vaccine | Rate of Healthy Adults Aged ≥19 ~ <65 Years and ≥65 Years With Seroprotection, Respectively. | Strain B Yamagata | 49.2 percentage of participants |
| IL-YANG Quadrivalent Influenza Vaccine | Rate of Healthy Adults Aged ≥19 ~ <65 Years and ≥65 Years With Seroprotection, Respectively. | Strain H3N2 | 69.8 percentage of participants |
| IL-YANG Quadrivalent Influenza Vaccine | Rate of Healthy Adults Aged ≥19 ~ <65 Years and ≥65 Years With Seroprotection, Respectively. | Strain H1N1 | 42.5 percentage of participants |
| IL-YANG Quadrivalent Influenza Vaccine | Rate of Healthy Adults Aged ≥19 ~ <65 Years and ≥65 Years With Seroprotection, Respectively. | Strain B Victoria | 44.7 percentage of participants |
| IL-YANG Quadrivalent Influenza Vaccine | Rate of Healthy Adults Aged ≥19 ~ <65 Years and ≥65 Years With Seroprotection, Respectively. | Strain H3N2 | 71.4 percentage of participants |
| IL-YANG Quadrivalent Influenza Vaccine | Rate of Healthy Adults Aged ≥19 ~ <65 Years and ≥65 Years With Seroprotection, Respectively. | Strain H1N1 | 35.7 percentage of participants |
| IL-YANG Quadrivalent Influenza Vaccine | Rate of Healthy Adults Aged ≥19 ~ <65 Years and ≥65 Years With Seroprotection, Respectively. | Strain B Yamagata | 57.1 percentage of participants |
| IL-YANG Quadrivalent Influenza Vaccine | Rate of Healthy Adults Aged ≥19 ~ <65 Years and ≥65 Years With Seroprotection, Respectively. | Strain B Victoria | 4.8 percentage of participants |
| IL-YANG Trivalent Influenza Vaccine | Rate of Healthy Adults Aged ≥19 ~ <65 Years and ≥65 Years With Seroprotection, Respectively. | Strain B Yamagata | 15.6 percentage of participants |
| IL-YANG Trivalent Influenza Vaccine | Rate of Healthy Adults Aged ≥19 ~ <65 Years and ≥65 Years With Seroprotection, Respectively. | Strain H3N2 | 73.3 percentage of participants |
| IL-YANG Trivalent Influenza Vaccine | Rate of Healthy Adults Aged ≥19 ~ <65 Years and ≥65 Years With Seroprotection, Respectively. | Strain H1N1 | 33.3 percentage of participants |
| IL-YANG Trivalent Influenza Vaccine | Rate of Healthy Adults Aged ≥19 ~ <65 Years and ≥65 Years With Seroprotection, Respectively. | Strain B Victoria | 44.4 percentage of participants |